AbbVie | Beneficio Bruto En Ventas



Gross Profit On Sales Cambio Fecha
AbbVie USD 10.71B 458M 2024-12
Abbott USD 5.92B 114M 2025-03
ALKERMES USD 257.31M 110.81M 2025-03
Amgen USD 5.54B 430M 2025-03
AstraZeneca USD 11.35B 819M 2025-03
Biogen USD 1.87B 44.1M 2024-12
BioMarin Pharmaceutical USD 593.59M 17.59M 2025-03
Bristol-Myers Squibb USD 8.18B 947M 2025-03
Eisai JPY 170.21B 16.72B 2024-12
Eli Lilly USD 10.5B 624.7M 2025-03
Gilead Sciences USD 5.99B 17M 2024-12
GlaxoSmithKline GBP 5.59B 34M 2025-03
J&J USD 14.6B 816M 2025-03
Medtronic USD 5.52B 49M 2025-01
Merck USD 12.77B 849M 2025-03
Neurocrine Biosciences USD 618.4M 4.3M 2024-12
Novartis USD 10.23B 294M 2024-12
Pacira USD 147.37M 17.66M 2024-12
Perrigo USD 385.9M 18.5M 2024-12
Pfizer USD 11.12B 987M 2025-03
Regeneron Pharmaceuticals USD 2.56B 659.4M 2025-03
Roche Holding CHF 11.69B 48M 2024-12
Sanofi EUR 7.72B 2.36B 2025-03
UCB EUR 970M 788M 2024-06
Ultragenyx Pharmaceutical USD 110.63M 37.35M 2025-03
United Therapeutics USD 701.9M 41.9M 2025-03
Vertex Pharmaceuticals USD 2.49B 109.3M 2024-12
Zoetis USD 1.6B 12M 2025-03



AbbVie Beneficio Bruto En Ventas - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - May 2025.